Physician profile
Eugene Choo
NPI 1376612846
$8,038.55
in general payments reported to CMS, 2019-2025
48 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $777 · 2021: $973 · 2022: $1,563 · 2023: $868 · 2024: $1,447 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,767.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $912.36 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $537.18 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.16 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $532.17 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $528.90 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $427.31 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $364.95 | 2019-2025 | |
| Amgen INC. | $306.09 | 2020-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $273.64 | 2019-2023 | |
| Boston Scientific Corporation | $235.00 | 2019-2025 | Watchman Flx |
| Amarin Pharma, INC. | $233.78 | 2019-2022 | |
| Biosense Webster, INC. | $233.58 | 2019-2024 | Carto 3 |
| Novo Nordisk INC | $211.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $201.78 | 2019-2022 | |
| Astellas Pharma US INC | $174.99 | 2020 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $173.67 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $160.56 | 2019-2024 | Brilinta, Farxiga |
| Shockwave Medical, INC | $159.29 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $158.24 | 2021-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $149.39 | 2020-2024 | Nexletol |
| Irhythm Technologies, INC. | $141.52 | 2019-2022 | |
| Cardiovascular Systems INC. | $131.77 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.90 | 2019-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $99.88 | 2024 | |
| Alnylam Pharmaceuticals INC. | $97.27 | 2020-2025 | Onpattro |
| Abiomed | $83.27 | 2024-2025 | Impella |
| Glaxosmithkline, LLC. | $73.76 | 2019-2025 | Shingrix, Arexvy |
| Kiniksa Pharmaceuticals, LTD. | $73.32 | 2021-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $72.97 | 2019-2025 | Opsynvi |
| Abbott Laboratories | $64.91 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Ge Healthcare | $60.89 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $55.88 | 2019 | |
| Baxter Healthcare | $54.93 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Angiodynamics, INC. | $52.29 | 2022-2025 | Alphavac |
| Daiichi Sankyo INC. | $50.98 | 2020-2023 | Injectafer |
| Bardy Diagnostics, INC. | $43.75 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $39.89 | 2024 | Arcalyst |
| Lundbeck LLC | $39.80 | 2019 | |
| Tactile Systems Technology INC | $24.06 | 2024 | Flexitouch Plus, Entre Plus |
| Impulse Dynamics (USA) INC. | $23.64 | 2022 | |
| Vital Connect, INC | $20.90 | 2024 | Vitalpatch Rtm |
| Getinge USA Sales, LLC | $20.35 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.28 | 2020 | |
| Allergan, INC. | $17.58 | 2020 | |
| Medtronic Vascular, INC. | $16.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.28 | 2019 | |
| Biotronik INC. | $12.28 | 2022 | |
| Gilead Sciences, INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Choo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.